arXiv
Interpretable Multi-Instance Learning Enables Early Prediction of Key Molecular Alterations from Routine Flow Cytometry in Acute Myeloid Leukemia
By Jonathan Legrand, Aguirre Mimoun, Baudouin Denis de Senneville and 3 others.
Abstract
Background
Molecular testing for NPM1 and FLT3-ITD mutations guides critical early treatment decisions in acute myeloid leukemia (AML), but results can take weeks, long after these decisions must be made. Flow cytometry, already performed within hours of admission as part of routine care, may carry enough signal to predict these mutations directly, without added cost or delay.